GleamWall
中文EN

REVB REVELATION BIOSCIENCES, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1810560 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-49.6%
TTM EPS YoY122.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-133.4%
ROA-106.3%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets27.8%
Debt / equity0.00x
Current ratio3.98x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.83x
Accruals ratio-18.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$1.51M$1.92M$1.38M$964,190$922,857$1.32M$858,830$605,504
SG&A expense$1.87M$1.74M$1.72M$1.61M$1.02M$1.14M$1.24M$1.15M
Operating income-$3.38M-$3.66M-$3.09M-$2.57M-$1.94M-$2.46M-$2.09M-$1.75M
Income tax$0——$0$0$0$0$0
Net income-$3.32M-$3.32M-$3.01M-$2.51M-$1.91M-$2.44M-$2.05M-$1.73M
EBITDA-$3.38M-$3.65M-$3.09M-$2.57M-$1.94M-$2.45M-$2.09M-$1.75M
EPS (basic)-5.92-0.87-2.71—-49.51-28.04-25.34—
EPS (diluted)-5.92-0.87-2.71—-49.51-28.04-25.34—
Weighted avg. shares (diluted)559,5963.83M3.21M—94,455200,66880,943—
Banking
Net interest income$68,063$82,159——$35,512$19,672——
Balance sheet
Cash & equivalents$9.12M$11.48M$14.11M$10.70M$12.71M$5.17M$3.70M$6.50M
Current assets$9.27M$11.68M$14.21M$10.81M$12.83M$5.36M$3.93M$6.57M
PP&E, net$163,847$172,032$140,717$18,067$23,919$35,170$42,390$56,332
Total assets$10.02M$12.50M$15.04M$11.58M$12.86M$5.40M$3.97M$6.62M
Current liabilities$2.33M$1.88M$1.42M$2.00M$1.85M$1.57M$1.09M$1.91M
Total liabilities$2.79M$2.43M$2.06M$2.72M$1.85M$1.57M$1.09M$1.91M
Shareholders' equity$7.23M$10.07M$12.99M$8.86M$11.00M$3.83M$2.88M$4.71M
Shares outstanding683,4423.91M3.91M226,3303.59M1.53M963,79643,526
Cash flow statement
Operating cash flow-$2.36M-$2.56M-$3.21M-$1.97M-$1.59M-$1.92M-$2.79M-$3.75M
Capital expenditure$0$39,628$71,879————-$17,689
Free cash flow-$2.36M-$2.60M-$3.29M————-$3.73M
Investing cash flow$0-$39,628-$71,879————$17,689
Financing cash flow$0-$33,802$6.70M-$41,166$9.12M——$3.69M
Depreciation & amortization$8,185$8,313$7,203$5,852$6,765$7,220$7,221$7,221
Stock-based compensation$482,229$401,417$470,997$370,166$874$873$223,455$72,566

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.